imipramine has been researched along with olanzapine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Jia, L; Sun, H | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Sen, S; Sinha, N | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Bojarski, AJ; Bucki, A; Chłoń-Rzepa, G; Jastrzębska-Więsek, M; Kołaczkowski, M; Partyka, A; Satała, G; Wasik, A; Wesołowska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Handzlik, J; Jankowska, A; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Kurczab, R; Nitek, W; Partyka, A; Satała, G; Siwek, A; Wesołowska, A; Żesławska, E | 1 |
| Bączek, T; Belka, M; Bojarski, A; Herold, F; Kleps, J; Kozioł, AE; Król, M; Nowak, G; Siwek, A; Ślifirski, G; Stachowicz, K; Szewczyk, B; Turło, J; Ulenberg, S | 1 |
| Bączek, T; Belka, M; Bojarski, A; Herold, F; Kleps, J; Kozioł, AE; Król, M; Nowak, G; Podsadni, P; Siwek, A; Ślifirski, G; Stachowicz, K; Szewczyk, B; Turło, J | 1 |
| Callaghan, JT; Cerimele, BJ; Hoyes-Beehler, PJ; Kassahun, KJ; Kondraske, GV; Nyhart, EH | 1 |
| Gaisler-Salomon, I; Green, A; Joel, D; Schiller, D; Weiner, I | 1 |
| Mendhekar, DN; Srilakshmi, P | 1 |
| Kenchaiah, BK; Kumar, S; Tharyan, P | 1 |
| Gold, L; Marston, HM; Martin, FD; Papp, M; Shahid, M; Wong, EH | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Elased, KM; Ligade, SS; Lucot, JB; Sharma, AN; Sharma, JN; Shukla, P | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
| Allen, C; Chial, HJ; Coughlan, C; Dhanasekaran, AR; Johnson, NR; Lucero, E; Markham, N; Potter, H; Sillau, S; Viltz, L; Wang, AC | 1 |
2 review(s) available for imipramine and olanzapine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for imipramine and olanzapine
| Article | Year |
|---|---|
Olanzapine: interaction study with imipramine.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Drug Interactions; Humans; Hypotension, Orthostatic; Imipramine; Male; Middle Aged; Olanzapine; Pirenzepine; Psychomotor Performance; Single-Blind Method | 1997 |
26 other study(ies) available for imipramine and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Mice; Purines; Receptor, Serotonin, 5-HT1A; Structure-Activity Relationship | 2015 |
Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
Topics: Animals; Antidepressive Agents; Behavior, Animal; Computer-Aided Design; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hydantoins; Male; Mice; Models, Molecular; Molecular Structure; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
Topics: Animals; Chemistry Techniques, Synthetic; Drug Design; Ligands; Mice; Pyrimidines; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Tryptamines | 2019 |
Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
Topics: Animals; Cells, Cultured; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; RNA-Binding Proteins; Structure-Activity Relationship; Tryptamines | 2019 |
A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clozapine; Conditioning, Psychological; Haloperidol; Imipramine; Inhibition, Psychological; Male; Models, Animal; Olanzapine; Paroxetine; Pirenzepine; Rats; Rats, Wistar; Swimming | 2003 |
Olanzapine-induced gynecomastia.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Capgras Syndrome; Drug Therapy, Combination; Gynecomastia; Hallucinations; Humans; Imipramine; Male; Olanzapine; Suicide, Attempted | 2005 |
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.
Topics: Antipsychotic Agents; Benzodiazepines; Ectoparasitic Infestations; Female; Fluoxetine; Haloperidol; Humans; Imipramine; Male; Middle Aged; Olanzapine; Pimozide; Retrospective Studies; Risperidone; Schizophrenia, Paranoid; Sertraline | 2010 |
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation.
Topics: Anhedonia; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chronic Disease; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Imipramine; Male; Olanzapine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Risperidone; Self Stimulation; Stress, Psychological | 2011 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Body Weight; Cholesterol; Depression; Eating; Female; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Imipramine; Liraglutide; Metabolic Diseases; Motor Activity; Olanzapine; Rats; Rats, Wistar; Swimming; Triglycerides | 2015 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Catalysis; Cognition; Humans; Imipramine; Olanzapine; Polymerization; Retrospective Studies | 2022 |